Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Reinforcing RAF

The theory behind the development of BAY 43-9006, a Raf kinase inhibitor in development by Onyx Pharmaceuticals Inc. and partner Bayer AG, is based on the knowledge that raf kinase is oncogenic in human cancers and is part of the

Read the full 404 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE